Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,798 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gel Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers

NCT00752141
View directory record Official record
Conditions
Healthy Volunteers
Interventions
oxybutynin chloride immediate-release, oxybutynin chloride topical gel, placebo
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
60 Years to 79 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
6
States / cities
Tucson, Arizona • National City, California • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2011 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Prevention and Treatment of Nausea Associated With Motion Sickness

NCT03986905
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine Nasal Gel, Placebo
Drug · Other
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 1 Interventional

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

NCT00821652
View directory record Official record
Conditions
Tumors
Interventions
NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

NCT01790126
View directory record Official record
Conditions
Prostate Cancer
Interventions
ARN-509, LHRH Agonist
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 25, 2026, 1:06 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers

NCT00318214
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Diabetes Complications
Interventions
MRE0094, Vehicle gel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 25, 2026, 1:06 PM EDT
Completed No phase listed Observational

A Study of the Effects of Molecular Diagnostic Directed Wound Gels on Wound Care Outcomes

NCT01319149
View directory record Official record
Conditions
Wounds
Interventions
Not listed
Lead sponsor
Southwest Regional Wound Care Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00613002
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
60
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction

NCT04984993
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
MED3000 (Male), Tadalafil 5mg (Male), MED3000 (Female), Tadalafil 5mg (Female)
Device · Drug
Lead sponsor
Futura Medical Developments Ltd.
Industry
Eligibility
22 Years to 70 Years · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 25, 2026, 1:06 PM EDT
Not listed Not applicable Interventional

Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses

NCT01900093
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Acthar Gel
Drug
Lead sponsor
Aaron Miller
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 25, 2026, 1:06 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus

NCT01498406
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
vitamin D
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design

NCT00357916
View directory record Official record
Conditions
Healthy
Interventions
PEP005 Topical Gel (0.01% concentration)
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin

NCT01139008
View directory record Official record
Conditions
Skin Manifestations
Interventions
metronidazole 1% gel, azelaic acid 15% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

NCT02237950
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel
Drug
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 3 Interventional

Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis

NCT03826550
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Diclofenac Sodium Gel, Solaraze 3% Topical Gel, Placebo
Drug · Other
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
24
States / cities
Bryant, Arkansas • San Ramon, California • Coral Gables, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 25, 2026, 1:06 PM EDT
Withdrawn Phase 3 Interventional

Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections

NCT02519140
View directory record Official record
Conditions
Gastric Cancer, Colon Cancer
Interventions
Cook Medical EMR Gel
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 25, 2026, 1:06 PM EDT
Terminated Phase 4 Interventional

Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease

NCT01738243
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Hyaluronic Acid Gel injection, Saline injection
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 25, 2026, 1:06 PM EDT
Recruiting Not applicable Interventional

Safety and Efficacy of Next Science Gel on Toenail Fungus

NCT04042857
View directory record Official record
Conditions
Onychomycosis of Toenail
Interventions
Next Science Treatment Gel
Device
Lead sponsor
Next Science TM
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

Multisite Controlled Trial of Cocaine Vaccine

NCT00969878
View directory record Official record
Conditions
Cocaine Dependence
Interventions
TA-CD Vaccination, Placebo Injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 25, 2026, 1:06 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

NCT06493578
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
VYN201 Gel, Vehicle Gel
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)

NCT03654885
View directory record Official record
Conditions
Glaucoma
Interventions
XEN-45 Gel Stent, Trabeculectomy
Device · Procedure
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
35
States / cities
Fayetteville, Arkansas • Arcadia, California • Culver City, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color

NCT03681470
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Aczone Gel
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 25, 2026, 1:06 PM EDT
Active, not recruiting Not applicable Interventional

Rectal Spacers Use in Prostate Cancer Radiation Therapy

NCT06594887
View directory record Official record
Conditions
Prostate Cancer
Interventions
SpaceOAR Vue, BioProtect Balloon Implant System
Device
Lead sponsor
Princeton ProCure management, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 1:06 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy

NCT00243789
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Pentoxifylline
Drug
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
7 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 25, 2026, 1:06 PM EDT